# Molecular contrast agents for post-infarct cardiac remodelling: a contemporary review

**Authors:** Pak Yin Lam, William D Watson, Ziad Mallat, Jason Tarkin

PMC · DOI: 10.1093/ehjimp/qyag019 · European Heart Journal. Imaging Methods and Practice · 2026-01-29

## TL;DR

This paper reviews molecular contrast agents for imaging heart changes after a heart attack, aiming to improve diagnosis and treatment.

## Contribution

The paper provides a contemporary review of molecular contrast agents for post-infarct cardiac remodelling and their potential clinical integration.

## Key findings

- Current imaging techniques lack the ability to characterize biological mechanisms of post-MI remodelling.
- Molecular tracers can target inflammation, angiogenesis, and scar formation for detailed imaging.
- The paper highlights the latest developments in molecular contrast agents for cardiac imaging.

## Abstract

Myocardial infarction (MI) is a leading cause of mortality, affecting 3.8% of the global population under 60 years of age, and 9.5% over 60 years. Adverse post-MI remodelling is the main contributor to heart failure, conferring a three- to six-fold increase in risk of premature death. Current imaging modalities, such as nuclear imaging and magnetic resonance imaging, provide structural and functional information of the heart and identify extracellular expansion for indirect estimation of infarct size. However, they do not characterize the exact biological mechanisms involved, nor the staging of disease progression. Molecular imaging aims to visualize the underlying processes of remodelling at a molecular and cellular level, aiding more accurate prognosis and targeted treatment. Molecular tracers, such as radioisotopes and paramagnetic nanoparticles, are modified to adhere to specific molecules or cells involved in inflammation, angiogenesis, and scar formation, which can be visualized and quantitatively assessed using positron-emission tomography and magnetic resonance imaging. This article provides an overview of the pathophysiology of adverse remodelling, the latest molecular contrast agents under development, and future directions for integration into clinical practice.

Graphical Abstract

## Linked entities

- **Diseases:** Myocardial infarction (MONDO:0005068), heart failure (MONDO:0005252)

## Full-text entities

- **Genes:** Pcsk9 (proprotein convertase subtilisin/kexin type 9) [NCBI Gene 100102] {aka FH3, HCHOLA3, Narc1, PC9}, REN (renin) [NCBI Gene 5972] {aka ADTKD4, HNFJ2, RTD}, Itgam (integrin alpha M) [NCBI Gene 16409] {aka CD11b/CD18, CR3, CR3A, Cd11b, F730045J24Rik, Ly-40}, SSTR2 (somatostatin receptor 2) [NCBI Gene 6752] {aka SST2}, Fap (fibroblast activation protein) [NCBI Gene 14089] {aka SIMP}, CD68 (CD68 molecule) [NCBI Gene 968] {aka GP110, LAMP4, SCARD1}, Cxcr4 (C-X-C motif chemokine receptor 4) [NCBI Gene 12767] {aka CD184, CXC-R4, CXCR-4, Cmkar4, LESTR, PB-CKR}, Cd68 (CD68 antigen) [NCBI Gene 12514] {aka Lamp4, Scard1, gp110}, Eln (elastin) [NCBI Gene 13717] {aka E030024M20Rik}, Chrna7 (cholinergic receptor, nicotinic, alpha polypeptide 7) [NCBI Gene 11441] {aka Acra7, alpha7, nAChR7, nAchR}, MYH1 (myosin heavy chain 1) [NCBI Gene 4619] {aka HEL71, MYHSA1, MYHa, MyHC-2X/D, MyHC-2x}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, Ly6g (lymphocyte antigen 6 family member G) [NCBI Gene 546644] {aka Gr-1, Gr1, Ly-6G}, TSPO (translocator protein) [NCBI Gene 706] {aka BPBS, BZRP, DBI, IBP, MBR, PBR}, RASA1 (RAS p21 protein activator 1) [NCBI Gene 5921] {aka CM-AVM, CMAVM, CMAVM1, GAP, PKWS, RASA}, LOX (lysyl oxidase) [NCBI Gene 4015] {aka AAT10}, Ptprc (protein tyrosine phosphatase receptor type C) [NCBI Gene 19264] {aka B220, CD45R, Cd45, L-CA, Ly-5, Lyt-4}, MAPK12 (mitogen-activated protein kinase 12) [NCBI Gene 6300] {aka ERK-6, ERK3, ERK6, MAPK 12, P38GAMMA, PRKM12}, CXCR4 (C-X-C motif chemokine receptor 4) [NCBI Gene 7852] {aka CD184, D2S201E, FB22, HM89, HSY3RR, LCR1}, Tspo (translocator protein) [NCBI Gene 12257] {aka Bzrp, IBP, PBR, Tspo1}, MPO (myeloperoxidase) [NCBI Gene 4353], TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, AGT (angiotensinogen) [NCBI Gene 183] {aka ANHU, SERPINA8, hFLT1}, Ccr2 (C-C motif chemokine receptor 2) [NCBI Gene 12772] {aka Cc-ckr-2, Ccr2a, Ccr2b, Ckr2, Ckr2a, Ckr2b}, DNAH8 (dynein axonemal heavy chain 8) [NCBI Gene 1769] {aka ATPase, SPGF46, hdhc9}, Nlrp3 (NLR family, pyrin domain containing 3) [NCBI Gene 216799] {aka AGTAVPRL, AII/AVP, Cias1, FCAS, FCU, MWS}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, Mpo (myeloperoxidase) [NCBI Gene 17523] {aka mKIAA4033}, CCR2 (C-C motif chemokine receptor 2) [NCBI Gene 729230] {aka CC-CKR-2, CCR-2, CCR2A, CCR2B, CD192, CKR2}
- **Diseases:** acute respiratory distress syndrome (MESH:D012128), acute (MESH:D000208), ischaemia (MESH:D007511), ST-elevation MI (MESH:D000072657), arrhythmias (MESH:D001145), hypoxic (MESH:D002534), ventricular dilatation (MESH:C566255), stroke (MESH:D020521), myocarditis (MESH:D009205), tumorigenesis (MESH:D063646), myocardial injury (MESH:D009202), diabetes (MESH:D003920), SD (MESH:D012735), malignancies (MESH:D009369), Alzheimer's (MESH:D000544), neuroinflammation (MESH:D000090862), graft-vs.-host disease (MESH:D006086), head, neck, and abdominal tumours (MESH:D006258), inability to work (MESH:D000073397), fibrosis (MESH:D005355), ischaemic injury (MESH:D014947), neurodegenerative disorders (MESH:D019636), Inflammatory (MESH:D007249), mitochondrial dysfunction (MESH:D028361), myocardial remodelling (MESH:D064752), sleep disturbances (MESH:D012893), myocardial necrosis (MESH:D009336), atherosclerotic plaques (MESH:D058226), cognitive decline (MESH:D003072), lymphoproliferative disease (MESH:D008232), infarct (MESH:D007238), HF (MESH:D006333), inflammatory bowel disease (MESH:D015212), amyloidosis (MESH:D000686), collagen (MESH:D003095), Coronary artery disease (MESH:D003324), contractile dysfunction (MESH:D006331), myocardial reperfusion injury (MESH:D015428), adverse remodelling (MESH:D020257), reduction in cardiac output (MESH:D002303), sarcoidosis (MESH:D012507), hypertrophy (MESH:D006984), myocardial tissue oedema (MESH:C536897), Acute Myocardial Infarction (MESH:D009203), idiopathic pulmonary fibrosis (MESH:D054990), CVD (MESH:D002318), cytotoxic (MESH:D064420), thrombosis (MESH:D013927), ischaemic (MESH:D018917), hypokinesia (MESH:D018476), atherosclerosis (MESH:D050197), hypertension (MESH:D006973), death (MESH:D003643)
- **Chemicals:** Superparamagnetic iron oxide (MESH:C000499), MCC950 (MESH:C000597426), 13C (MESH:C000615229), chloride (MESH:D002712), aldehydes (MESH:D000447), Technetium-99m sestamibi (MESH:D017256), 18F-fluciclatide (MESH:C530281), 18F (MESH:C000615276), 68Ga-NODAGA-RGD (MESH:C561299), acetyl-coenzyme A (MESH:D000105), 89Zirconium (MESH:C000615502), 18F-GE180 (MESH:C000708863), Cy5.5 (MESH:C098793), lactate (MESH:D019344), 68Ga-DOTATATE (MESH:C513399), 64Cu (MESH:C000615411), polyglucose (MESH:D005936), 2-deoxyglucose (MESH:D003847), hypochlorous acid (MESH:D006997), aldosterone (MESH:D000450), tritium (MESH:D014316), rubidium (MESH:D012413), 18F-galacto-RGD (MESH:C423503), pyruvate (MESH:D019289), -pentixafor (MESH:C000597686), Evolocumab (MESH:C577155), Tc-99m (MESH:D013667), oxygen (MESH:D010100), DOTA (MESH:C071349), Ferumoxytol (MESH:D052203), eosin (MESH:D004801), AMD3100 (MESH:C088327), ROS (MESH:D017382), GE180 (MESH:C571664), glucose (MESH:D005947), carbon dioxide (MESH:D002245), Gd (MESH:D005682), EP-3533 (MESH:C000706187), NS14490 (MESH:C584300), 68Ga-NOTA-RGD (MESH:C584295), 68Ga (MESH:C000615430), bicarbonate (MESH:D001639), AMD (MESH:D008750), chlorine (MESH:D002713), lipoxins (MESH:D044045), H&amp;E (MESH:D006371), FAPI (-), haematoxylin (MESH:D006416), RGD (MESH:C047981), atorvastatin (MESH:D000069059), Gd-DTPA (MESH:D019786)
- **Species:** Sus scrofa (pig, species) [taxon 9823], Mus musculus (house mouse, species) [taxon 10090], Oryctolagus cuniculus (domestic rabbit, species) [taxon 9986], Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12914465/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12914465/full.md

## References

61 references — full list in the complete paper: https://tomesphere.com/paper/PMC12914465/full.md

---
Source: https://tomesphere.com/paper/PMC12914465